Display options
Cite
Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015;88(6):1427-1433doi: 10.1038/ki.2015.270.
Bushinsky, D. A., Williams, G. H., Pitt, B., Weir, M. R., Freeman, M. W., Garza, D., Stasiv, Y., Li, E., Berman, L., & Bakris, G. L. (2015). Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney international, 88(6), 1427-1433. https://doi.org/10.1038/ki.2015.270
Bushinsky, David A, et al. "Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia." Kidney international vol. 88,6 (2015): 1427-1433. doi: https://doi.org/10.1038/ki.2015.270
Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015 Dec;88(6):1427-1433. doi: 10.1038/ki.2015.270. Epub 2015 Sep 16. PMID: 26376130; PMCID: PMC4678168.
Copy Download .nbib Format: NLM
Share it on

Kidney Int. 2015 Dec;88(6):1427-1433. doi: 10.1038/ki.2015.270. Epub 2015 Sep 16.

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.

Kidney international

David A Bushinsky, Gordon H Williams, Bertram Pitt, Matthew R Weir, Mason W Freeman, Dahlia Garza, Yuri Stasiv, Elizabeth Li, Lance Berman, George L Bakris

Affiliations

  1. Division of Nephrology, University of Rochester School of Medicine, Rochester, New York, USA.
  2. Department of Medicine - Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  3. University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
  4. Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  5. Department of Medicine, Massachusetts General Hospital, Harvard University, Boston, Massachusetts, USA.
  6. Relypsa, Redwood City, California, USA.
  7. PharmaStat, Newark, California, USA.
  8. Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, Illinois, USA.

PMID: 26376130 PMCID: PMC4678168 DOI: 10.1038/ki.2015.270

Abstract

Patients with chronic kidney disease (CKD) have a high risk of hyperkalemia, which increases mortality and can lead to renin-angiotensin-aldosterone system inhibitor (RAASi) dose reduction or discontinuation. Patiromer, a nonabsorbed potassium binder, has been shown to normalize serum potassium in patients with CKD and hyperkalemia on RAASi. Here, patiromer's onset of action was determined in patients with CKD and hyperkalemia taking at least one RAASi. After a 3-day potassium- and sodium-restricted diet in an inpatient research unit, those with sustained hyperkalemia (serum potassium 5.5 - under 6.5 mEq/l) received patiromer 8.4 g/dose with morning and evening meals for a total of four doses. Serum potassium was assessed at baseline (0 h), 4 h postdose, then every 2-4 h to 48 h, at 58 h, and during outpatient follow-up. Mean baseline serum potassium was 5.93 mEq/l and was significantly reduced by 7 h after the first dose and at all subsequent times through 48 h. Significantly, mean serum potassium under 5.5 mEq/l was achieved within 20 h. At 48 h (14 h after last dose), there was a significant mean reduction of 0.75 mEq/l. Serum potassium did not increase before the next dose or for 24 h after the last dose. Patiromer was well tolerated, without serious adverse events and no withdrawals. The most common gastrointestinal adverse event was mild constipation in two patients. No hypokalemia (serum potassium under 3.5 mEq/l) was observed. Thus, patiromer induced an early and sustained reduction in serum potassium and was well tolerated in patients with CKD and sustained hyperkalemia on RAASis.

References

  1. South Med J. 2009 May;102(5):493-7 - PubMed
  2. J Am Soc Nephrol. 1998 Oct;9(10):1924-30 - PubMed
  3. N Engl J Med. 1961 Jan 19;264:115-9 - PubMed
  4. Ren Fail. 2013;35(2):185-8 - PubMed
  5. JAMA. 2009 Oct 21;302(15):1658-65 - PubMed
  6. Burns. 2002 Mar;28(2):189-90 - PubMed
  7. Int J Nephrol. 2012;2012:940320 - PubMed
  8. Am J Med Sci. 2014 Feb;347(2):93-100 - PubMed
  9. J Am Soc Nephrol. 2010 May;21(5):733-5 - PubMed
  10. Postgrad Med J. 1992 Apr;68(798):302 - PubMed
  11. N Engl J Med. 2004 Aug 5;351(6):543-51 - PubMed
  12. J Hosp Med. 2011 Mar;6(3):136-40 - PubMed
  13. Arch Intern Med. 2009 Jun 22;169(12):1156-62 - PubMed
  14. Ren Fail. 2012;34(9):1095-9 - PubMed
  15. Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12-154 - PubMed
  16. J Nephrol. 2015 Apr;28(2):165-72 - PubMed
  17. Discov Med. 2014 Nov;18(100):249-54 - PubMed
  18. Eur Heart J. 2011 Apr;32(7):820-8 - PubMed
  19. Am J Kidney Dis. 1992 Aug;20(2):159-61 - PubMed
  20. Lancet. 1966 Jan 22;1(7430):167-9 - PubMed
  21. Am J Med. 2013 Mar;126(3):264.e9-24 - PubMed
  22. Kidney Int. 1993 Jan;43(1):212-7 - PubMed
  23. CMAJ. 2010 Oct 19;182(15):1631-5 - PubMed
  24. Clin Cardiol. 2012 Jan;35(1):32-6 - PubMed
  25. N Engl J Med. 2004 Aug 5;351(6):585-92 - PubMed
  26. Future Cardiol. 2012 Jan;8(1):17-28 - PubMed
  27. N Engl J Med. 2015 Jan 15;372(3):211-21 - PubMed
  28. Kidney Int. 2002 Jul;62(1):1-9 - PubMed
  29. Rev Cardiovasc Med. 2014;15(1):11-23 - PubMed
  30. JAMA. 2015 Jul 14;314(2):151-61 - PubMed

Publication Types